GAITHERSBURG, Md., Nov. 25, 2020(GLOBE NEWSWIRE) -- Novavax Inc.(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion in each conference.
Piper Sandler 32nd Annual Virtual Healthcare ConferencePanelDate: |
Tuesday, December 1, 2020
Time: | 10:00 a.m. Eastern Time (ET)
Panel title: | The Road Ahead for COVID-19 Vaccines: What We Know and Questions Still to Be Answered into 2021
Moderators: | Edward A. Tenthoff and Yasmeen Rahimi, Ph.D.
NVAX Panelist: | Gregory M. Glenn, M.D., President of Research and Development, Novavax
Additional panelists: Moderna, Inc., Arcturus Therapeutics Holdings, Inc. and Altimmune, Inc.
This event is open to Piper Sandler clients |
Conference |
Event:
Participants: | Fireside chat
Stanley C. Erck, President and Chief Executive Officer, and Dr. Glenn
Webcast:
| A replay of the recorded fireside session is available through the
events page of the Company’s website at
ir.novavax.com for 90 days.
|
Event:
Date:
| Investor meetings
Wednesday, December 2, 2020
Evercore ISI 3rd Annual HealthCONx ConferenceDate: | Thursday, December 3, 2020
Time: | 2:15 p.m. Eastern Time (ET)
Participation: | Fireside chat and investor meetings
Live webcast: |
www.novavax.com, “Investors”/ “Events”
|
